Upload
others
View
2
Download
0
Embed Size (px)
Citation preview
Hepatitis C: Retreatment and resistance
Will Irving
University of Nottingham
ESCMID eLibrary
©
by author
Viral resistance
RAV Resistance associated variant
RAS Resistance associated substitution
Viral mutations which make the virus less susceptible to treatment
Pre-existing RAS polymorphisms
Treatment Emergent RAS selected by treatment
ESCMID eLibrary
©
by author
Resistance: Principles
• Monotherapy will result in selection of mutations which enhance replication in presence of drug – Darwinian selection
ESCMID eLibrary
©
by author
Resistance: data interpretation
• Resistance data are difficult to present and difficult to interpret (!)
• RAS may be specific to • A whole drug class
• Individual specific drugs
• Genotype specific
• Sub-genotype specific
ESCMID eLibrary
©
by author
Lontok et al. Hepatology 2015; 62: 1623-1632
Gt 1a
Gt 1b
Gt 3
ESCMID eLibrary
©
by author
Resistance: Principles
• Monotherapy will result in selection of mutations which enhance replication in presence of drug – Darwinian selection
• Resistance is NOT all or none – hence “fold-resistance”
ESCMID eLibrary
©
by author
AASLD HCV Guidance – Resistance Primer https://www.hcvguidelines.org/evaluate/resistance ESCMID eLibrary
©
by author
Presentation title - edit in Header and Footer
Clinically relevant NS5A resistance-associatedsubstitutions (RASs)
Sorbo et al Drug Resist Update 37: 17 2018 ESCMID eLibrary
©
by author
Resistance testing: How?
• Sequencing of relevant sections of the genome
• Standard PCR-based – Sanger – sequencing• Also known as Population sequencing
• Technically straightforward, may labs capable
• Will only detect populations present at >20%
• Next generation sequencing (aka deep seq)• Can detect minority species down to 1%
• Technically very exacting, and requires considerable bioinformatics expertise to interpret the data
ESCMID eLibrary
©
by author
UK NS5a RAS prevalence data (Dr D Bradshaw, Public Health England)• 635 pre-treatment samples NS5a sequenced
Number %
≥ 1 NS5A RAS
Overall 104 16.4
Treatment-naive* 74 14.6
Treatment-experienced‡ 22 25.9
Prior PEG/RBV 5 13.2
DAAs: Non-NS5A inhibitor containing 3 17.6
DAAs: NS5A inhibitor containing 11 50.0
Regimen unknown 3 37.5
≥ 2 NS5A RASs 17 2.7 ESCMID eLibrary
©
by author
Prevalence of HCV NS5A RASs at positions 28, 30, 31, 58 or 93
11 Surveillance of resistance to HCV NS5A inhibitors
0
1
2
3
4
5
6
7
8
9
10
M28 Q30 L31 H58 Y93
% o
f sa
mp
les
con
tain
ing
mu
tati
on
Treatment history not known
Prior DAA: NS5Ai
Prior DAA: non NS5Ai
Prior PEG/RBV
Treatment-naïve
V (47)T (6)
AV, AT (1)
R (18)H (10)L (1)
H (10)C, N (4)
S (3)FHL (1)
M (10) D (3)ADP, DN, R (1)
Brackets denote total number ESCMID eLibrary
©
by author
Resistance testing: How?
• Sequencing identifies possible RAS but doesn’t give any information about their effect on drug sensitivity
• In vitro susceptibility testing• Difficult to do
• Introduce specific mutations into replicon system and test effect of different drug concentrations on viral replication
• Correlation between in vitro data and in vivo significance is not perfect!
ESCMID eLibrary
©
by author
Resistance testing: Why?
• Knowledge of RAS may influence clinical management:
(1) Alter duration of therapy
(2) Add ribavirin
(3) Choose particular DAA regimen (for retreatment, see later)
ESCMID eLibrary
©
by author
SVR12 rates for HCV genotype 1a−infected patients with or without NS5A RASs across different elbasvir and grazoprevir
(Zepatier) regimens
14 Surveillance of resistance to HCV NS5A inhibitors
98
70
99
61
100
56
100 100
0
20
40
60
80
100
441/450 39/56 132/133 11/18 56/56 5/9 67/67 6/6
All 12W no RBV All 12W + RBV 16 or 18W no RBV 16 or 18W + RBV
Sust
ain
ed
vir
olo
gic
resp
on
se (
%)
Any RAS
No RAS
Komatsu et al Gastroenterology 152: 586 2017 ESCMID eLibrary
©
by author
ZEPATIER
• Data sheet for Genotype 1a• “ZEPATIER for 16 weeks should be considered in patients
with …… specific NS5A polymorphisms causing at least a 5-fold reduction in activity of Elbasvir to minimise the risk of treatment failure
ESCMID eLibrary
©
by author
Resistance testing: When?
• Universal testing of all patients pre-treatment• This is the model for HIV
• BUT – SVR rates approach 100% for most patients on most regimens
• There are NO recommendations for this
• Selective• Only test those patients where knowledge of the results may influence clinical
management
• But which patients are those?
• Learned Society Recommendations
ESCMID eLibrary
©
by author
AASLD September 2017:https://www.hcvguidelines.org/evaluate/resistance
Geno 3 patients; Sof/Dac or Sof/Vel; TE or cirrhosis; if Y93H present add weight-based ribavirin
TE = Treatment experiencedTN = Treatment naive
ESCMID eLibrary
©
by author
EASL Recommendations April 2018:Article in press, Journal of Hepatology
Access to reliable HCV resistance testing is limited and there is no consensus on the techniques, interpretation and reporting of these tests.
Testing for HCV resistance prior to treatment is not recommended
Applies also to treatment-experienced patients – defined as patients who were previously treated with PEG/RBV; PEG/RBV/SOF; SOF/RBV
? Of value in patients who have failed DAA therapy? ESCMID eLibrary
©
by author
Patients who have failed DAA-containing therapy: Re-treatment• Does it work?
• Is resistance testing helpful?
ESCMID eLibrary
©
by author
Retreatment: Does it work?
Bourliere M et al. NEJM June 2017;376: 2134-46
Wyles D et al. Hepatology Feb 2018; 67: 514-523
Poordad F et al. Hepatology April 2018;76: 1253-60 ESCMID eLibrary
©
by author
Polaris-1 and Polaris-4 trials NEJM June 2017;376: 2134-46
• Polaris-1 - Patients TE with NS5a inhibitors n = 264• Pts treated with Sof/Vel/Vox 12 weeks
• Polaris 4 – Patients TE with NS3/NS5b inhibitors n = 333• Pts treated with Sof/Vel/Vox 12 weeks OR Sof/Vel 12 weeks
ESCMID eLibrary
©
by author
Polaris 1
• TE with NS5a inhibitors
• Overall SVR 96%
• Geno 3 SVR 95%
• No cirrhosis 99%
• Cirrhosis 93%
• 83% had NS3/NS5a RAS SVR 97%
• 17% had no RAS SVR 98%
ESCMID eLibrary
©
by author
Polaris-4
• TE with NS3/NS5b inhibitors
• Overall SVR:
• S/V/V 98% versus S/V 90%
• S/V/V – geno not important
• S/V/V cirrhosis not important
• NS3/NS5a RAS had no effect
ESCMID eLibrary
©
by author
Surveyor-II Part 3 studyWyles D et al. Hepatology Feb 2018; 67: 514-523
• Genotype 3 patients , previous Rx = PEG/RBV or Sof/RBV +/- PEG
• i.e. previous NS3 or NS5a treated patients were excluded
ESCMID eLibrary
©
by author
ESCMID eLibrary
©
by author
7 of 8 patients with baseline Y93H achieved SVR ESCMID eLibrary
©
by author
Magellan-1 Part 2 studyPoordad F et al. Hepatology April 2018;76: 1253-60
• Pts with g1, 4, 5, 6
• Only 14% had cirrhosis
• Past treatment with NS5a and or NS3 inhibitor (didn’t include any Zepatier or Sof-Vel failures)
• Retreatment with Gle-Pib for 12 or 16 weeks
ESCMID eLibrary
©
by author
ESCMID eLibrary
©
by author
Magellan-1 Part 2 study: Results• Gle-Pib 12 weeks n = 44 SVR 89%
• Gle-Pib 16 weeks n = 47 SVR 91%
• Baseline RAS SVR• None or NS3 only n=32 100%
• NS5a alone n=47 12 weeks 83% 16 weeks 96%
• NS3 and NS5a n=9 12 weeks 80% (4/5) 16 weeks 25% (1/4)
• Conclusion• 16 weeks Gle-Pib achieved high rates of SVR in g1 patients who had
previously failed NS5a and/or NS3 inhibitor DAA regimens
EASL 2018 recommendations: “The MAGELLAN-1 trial showed that the combination of Gle and Pib does not have a high enough barrier-to-resistance to achieve optimal SVR rates in patients previously exposed to an NS5A inhibitor.” ESCMID eLibrary
©
by author
Real-World data:Halfon et al J Hep 2018; 68: 595-76 centres France
24 patients, 20 with NS5a RAS, 96% SVR
ESCMID eLibrary
©
by author
Halfon et al J Hep 2018; 68: 595-7
ESCMID eLibrary
©
by author
EASL recommendations for retreatment (Apr 18)
Patients without cirrhosis or with compensated cirrhosis who failed after a DAA (PI and/or NS5A inhibitor)-containing regimen should be retreated with Sof/Vel/Vox for 12 weeks ….
HCV resistance testing prior to retreatment in patients who failed after any of the DAA-containing treatment regimens is useful to guide retreatment ……
If there are predictors of lower response (advanced liver disease, multiple courses of DAA-based treatment, complex NS5A RAS profile), …. (use) the combination of sofosbuvir plus the fixed-dose combination of glecaprevir and pibrentasvir for 12 weeks
In very difficult-to-cure patients (patients with NS5A RASs who failed twice to achieve SVR after aregimen including a PI and/or an NS5A inhibitor), the combination of Sof/Vel/Vox, or the triple combination of Sof + Gle-Pib can be administered for 12 weeks with weight-based RBV and/or treatmentduration can be prolonged to 16 to 24 weeks ESCMID eLibrary
©
by author
Factors influencing response to DAAs
• Genotype
• Cirrhosis
• Prior treatment experience
ESCMID eLibrary
©
by author
How diverse is HCV?
Smith et al, Hepatology 2014
• 7 distinct genotypes
(1-7) - differ by >30%
• 84 subtypes (e.g. 1a, 1b etc) – differ by >15%
• quasispecies – differ by <15%
gt1
gt6
gt2
gt7
gt3
gt5
gt4
ESCMID eLibrary
©
by author
Numbers of HCV genotypes and subtypes
Genotype No. of subtypesUnassigned
isolates
gt1 13 7
gt2 15 8
gt3 8 1
gt4 18 10
gt5 1 0
gt6 28 16
gt7 1 0
Total 84 42
There are also 9 recombinant HCV genomes (6x gt2/gt1; 1x gt2/gt5; 2x gt2/gt6) ESCMID eLibrary
©
by author
The gap in HCV genomic data in LMICs
Niebel et al., Lancet Gastro and Hepatol 2017
NS3 sequences
NS5A sequences
NS5B sequences
ESCMID eLibrary
©
by author
447
AH D-Ia D-Ib LCS-I
LCS-II
D-II D-III
1 21310129 250 342 356
Posn of NS5A RAS
HCV GtSubjects/
ReferenceDAA Rx
1o Rx
Outcome
2o Rx
OutcomeTime 28 29 30 31 32 58 93
Gt1a Gt1a Ref M P Q L P H Y
Gt1b Gt1b Ref L P R L P P Y
Gt1l
P1SOF/LDV/
RbnResp-Rel Resp-Rel
Pre-Rx M P R M P P Y
Post-Rx M P R M P P Y
P2 SOF/DCV Resp-Rel Resp-RelPre-Rx M P Q M P P Y
Post-Rx NA
P3SOF/LDV/
RbnResp-Rel Resp-Rel
Pre-Rx M P R M P P Y
Post-Rx M P R M P P Y
NHE England Early Access Programme: Decompensated patients. Pre- and post-Rx sequences for gt1l patients
NS5A DAAbinding
Posn. 28 29 30 31 32 33 34 35
GT1a M P Q L P G I P
58
H
93
Y
Filipe et al., J Hepatol 2017 ESCMID eLibrary
©
by author
Posn of NS5A RAS
HCV GtSubjects/
ReferenceDAA Rx
1o Rx
Outcome
2o Rx
OutcomeTime 28 29 30 31 32 58 93
Gt1a Gt1a Ref M P Q L P H Y
Gt1b Gt1b Ref L P R L P P Y
Gt1l
P1SOF/LDV/
RbnResp-Rel Resp-Rel
Pre-Rx M P R M P P Y
Post-Rx M P R M P P Y
P2 SOF/DCV Resp-Rel Resp-RelPre-Rx M P Q M P P Y
Post-Rx NA
P3SOF/LDV/
RbnResp-Rel Resp-Rel
Pre-Rx M P R M P P Y
Post-Rx M P R M P P Y
Pre- and post-Rx sequences for gt1l patients
Posn of NS5A RASNS5A DAA
(fold resistance)
28 29 30 31 32 LDV DCV Vel
Gt1awt M P Q L P 1 1 1
Gt1amut M P R M P >23,400 >4,452 200
Wyles et al., J Hepatol 2013 ESCMID eLibrary
©
by author
Posn of NS5A RAS
HCV GtSubjects/
ReferenceDAA Rx
1o Rx
Outcome
2o Rx
OutcomeTime 28 29 30 31 32 58 93
Gt1a Gt1a Ref M P Q L P H Y
Gt1b Gt1b Ref L P R L P P Y
Gt1l
P1SOF/LDV/
RbnResp-Rel Resp-Rel
Pre-Rx M P R M P P Y
Post-Rx M P R M P P Y
P2 SOF/DCV Resp-Rel Resp-RelPre-Rx M P Q M P P Y
Post-Rx NA
P3SOF/LDV/
RbnResp-Rel Resp-Rel
Pre-Rx M P R M P P Y
Post-Rx M P R M P P Y
Gt4a Gt4a ref V P L M P P Y
Gt4r
P4 SOF/LDV Non-RespNot
re-treated
Pre-Rx M P R M P P Y
Post-Rx M P R M P P Y
P5SOF/LDV/
RbnResp-Rel
Not
re-treated
Pre-Rx M P R L P P Y
Post-Rx M P R L P P H
Pre- and post-Rx sequences for gt1l and gt4r patients
Filipe et al., J Hepatol 2017 ESCMID eLibrary
©
by author
How variable are the DAA resistance sites in gt1l and gt4r?
NS5A 28 29 30 31 32
Gt1a (n=4983) M (96%) P (100%) Q (96%) L (99%) P (100%)
Gt1b (n=4706) L (99%) P (100%) R (92%) L (96%) P (100%)
Gt1l (n=12)M P
R (n=5)M P
Q (n=6)
T (n=1) P Q M P
Aranday-Cortes et al., unpublished ESCMID eLibrary
©
by author
How variable are the DAA resistance sites in gt1l and gt4r?
NS5A 28 29 30 31 32
Gt1a (n=4983) M (96%) P (100%) Q (96%) L (99%) P (100%)
Gt1b (n=4706) L (99%) P (100%) R (92%) L (96%) P (100%)
Gt1l (n=12)M P
R (n=5)M P
Q (n=6)
T (n=1) P Q M P
Gt4r (n=27)
n=3 M P R M P
n=4 V P R M P
n=9 M P R L P
n=8 V P R L P
n=2 M P R V P
n=1 I P R L P ESCMID eLibrary
©
by author
Genotype Frequency Percentage (100%)
1 8 12.7
1a 4 6.3
1b 6 9.5
1c 1 1.6
1e 2 3.2
1g 1 1.6
1l 3 4.8
2r 1 1.6
3a 5 7.9
3h 1 1.6
4b 2 3.2
4f 2 3.2
4g 1 1.6
4k 3 4.8
4m 1 1.6
4r 16 25.4
4v 5 7.9
5a 1 1.6
Total 63 100.0
Percentage Genotype Distribution
Genotypes 1a, 1b and 3a account for only 23/63 (37%) of samples from UK patients born in Africa
ESCMID eLibrary
©
by author
African unassigned gt1 isolates that did not respond to DAAs
gt1agt1b
2 patients of African origin, failed DAA therapy
Leitch et al., unpublished ESCMID eLibrary
©
by author
Overall summary
• Expect 95% or greater HCV-infected patients to achieve SVR
on first treatment
• Resistance testing is indicated in some specific
circumstances (eg pre-Zepatier) - AASLD
• Resistance testing should be restricted to those patients
who have failed DAA-containing regimens - EASL
• Patients who have failed DAA regimens can be retreated
with high SVR rates
• Incomplete record of HCV diversity could influence selection
of DAAs used in certain global regions
• Rare subtypes in some ethnic groups may be problematic to
treat ESCMID eLibrary
©
by author
Acknowledgements
UK NS5a resistance prevalence dataDr Dan Bradshaw Public Health EnglandDr Tamyo Mbisa
Rare subtype dataProf John McLaughlan Centre for VirusDr Carol Leitch for Research, GlasgowDr Ana Felippe University
Kazeem Adeboyejo University of Nottingham
ESCMID eLibrary
©
by author
ESCMID eLibrary
©
by author